Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZPUSO)

• Drug Name: PMID24900749C1a Drug Info
• Synonyms: GTPL8128; BDBM50437434

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 72163809
  TTD Drug ID: DMZPUSO

Molecule-Related Drug Atlas

Drug(s) Targeting PIM-3 protein kinase (PIM3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9682991, 23	DMGTIP6	N. A.	N. A.	Patented	[2]
US8889696, Staurosporine	DMSYUHK	N. A.	N. A.	Patented	[3]
US8829193, 3	DM5ZGK3	N. A.	N. A.	Patented	[4]
BDBM50061601	DMQ4TUE	N. A.	N. A.	Patented	[5]
US9580418, Example 8	DMGH9B3	N. A.	N. A.	Patented	[6]
BDBM50061608	DM3MRD9	N. A.	N. A.	Patented	[5]
US8481586, 15	DMFEUMZ	N. A.	N. A.	Patented	[7]
US9434725, 315	DM316FB	N. A.	N. A.	Patented	[8]
BDBM50061612	DMM8IDC	N. A.	N. A.	Patented	[5]
US8669361, 102	DM4G3OC	N. A.	N. A.	Patented	[9]

Drug(s) Targeting Casein kinase II alpha (CSNK2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CX-4945	DMWE7B9	Coronavirus infection	1D92	Phase 2	[10]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[11]
EMODIN	DMAEDQG	Coronavirus Disease 2019 (COVID-19)	1D6Y	Terminated	[12]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[13]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[12]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[12]
APIGENIN	DMI3491	Discovery agent	N.A.	Investigative	[12]
AdoC(Dpr)2AlaArg6	DM2TWSZ	Discovery agent	N.A.	Investigative	[14]
PMID22115617C2c	DMX5UKA	Discovery agent	N.A.	Investigative	[15]
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole	DM3JB6S	Discovery agent	N.A.	Investigative	[12]

Drug(s) Targeting Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Harmine	DMPA5WD	Discovery agent	N.A.	Patented	[16]
PMID28766366-Compound-Scheme21Left	DMWTRUK	N. A.	N. A.	Patented	[16]
PMID28766366-Compound-Scheme21Right	DMF3X40	N. A.	N. A.	Patented	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Casein kinase II alpha (CSNK2A1)	TTER6YH	CSK21_HUMAN	Inhibitor	[1]
Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3)	TTV4EX0	DYRK3_HUMAN	Inhibitor	[1]
Homeodomain interacting protein kinase 2 (HIPK2)	TTOB49C	HIPK2_HUMAN	Inhibitor	[1]
PIM-3 protein kinase (PIM3)	TTCGOIN	PIM3_HUMAN	Inhibitor	[1]

References

• [1] Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5.
• [2] Tricyclic compounds for use as kinase inhibitors. US9682991.
• [3] Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof. US8889696.
• [4] PIM kinase inhibitors and methods of their use. US8829193.
• [5] Azole compounds as PIM inhibitors. US9321756.
• [6] Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors. US9580418.
• [7] Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors. US8481586.
• [8] 5-azaindazole compounds and methods of use. US9434725.
• [9] Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US9573943.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A. J Med Chem. 1996 Dec 20;39(26):5215-27.
• [12] Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
• [13] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [14] Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
• [15] CK2alpha and CK2alpha' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem. 2012 Jan;47(1):345-50.
• [16] Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.